Genomic ancestry as a predictor of haemodynamic profile in heart failure

Sabrina Bernardez-Pereira1, Luciana Gioli-Pereira2, Fabiana G Marcondes-Braga2

  • 1Fluminense Federal University, Niteroi, Rio de Janeiro, Brazil; Heart Institute, University of São Paulo Medical School, Sao Paulo, Brazil.

Open Heart
|August 23, 2016
PubMed

Insights

Genetic ancestry, not self-declared race, impacts heart failure (HF) hemodynamics. African ancestry links to worse diastolic function, while Amerindian ancestry correlates with impaired ventricular contractility in HF patients.

Area of Science:

  • Cardiology
  • Genetics
  • Physiology

Background:

  • Chronic heart failure (HF) is a complex condition with diverse patient profiles.
  • Understanding the influence of genetic and demographic factors on HF pathophysiology is crucial for personalized medicine.

Purpose of the Study:

  • To investigate the association between genetic ancestry, self-declared race, and hemodynamic parameters in patients with chronic heart failure (HF).

Main Methods:

  • Cross-sectional study of 362 HF patients (aged 18-80, ejection fraction ≤50%).
  • Genetic analysis of ancestry informative markers and estimation of genomic ancestry (European, African, Native American).
  • Echocardiography and impedance cardiography (ICG) for hemodynamic assessment; race self-classified as white or non-white.

Main Results:

  • No significant differences in ICG parameters based on self-declared race.
  • Amerindian ancestry correlated positively with systolic time ratio (r=0.109, p<0.05).
  • African ancestry showed positive correlations with thoracic fluid content index (r=0.124, p<0.05), E wave peak (r=0.127, p<0.05), and E/e' ratio (r=0.197, p<0.01).
  • African ancestry remained associated with the E/e' ratio in multivariate analysis.

Conclusions:

  • African genetic ancestry is linked to poorer diastolic function parameters in HF.
  • Amerindian ancestry correlates with an impaired ventricular contractility pattern.
  • Self-declared race is insufficient for predicting hemodynamic profiles in HF patients.
Abstract

Keywords:
HEART FAILURE

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.5K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
618
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
688